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Introduction {#sec1}
============

Long noncoding RNAs (lncRNAs) are a class of noncoding transcripts over 200 nucleotides in length. They are expressed in a highly tissue- and disease-specific manner and play critical roles in development and disease ([@bib9], [@bib9], [@bib17], [@bib16], [@bib25], [@bib32]). In cancer, dysregulated lncRNAs can function either as oncogenes ([@bib2], [@bib15], [@bib56]) or tumor suppressors ([@bib24], [@bib58]). LncRNAs have emerged as critical regulators of gene expression, with their activity largely governed by absolute expression levels, interacting partners, and subcellular localization ([@bib18]).

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy in the United States, with less than 50% of patients surviving more than 5 years ([@bib49]). This is largely due to lack of effective targeted therapies for treatment of EOC, which is often drug resistant when it recurs. So far, a handful of lncRNAs have been implicated in EOC. *H19* and *HOTAIR* are expressed in ovarian tumors ([@bib47], [@bib52]), and *MEG3*, *DNM3OS*, and *MIAT* are critical for epithelial-to-mesenchymal transition ([@bib39]). However, the underlying functional mechanisms of lncRNAs in EOC development remains poorly understood and their prospects as therapeutic targets for ovarian cancer unexplored.

For each tumor type there are typically thousands of dysregulated lncRNAs, but there is currently no consensus on the most efficient approach to identifying and characterizing the most critical players in disease development. Here, we implement a strategy for prioritization and characterization of lncRNAs implicated in cancer. The "LncRNA Interpreter" approach combines functional proteomics with interactome profiling to characterize the functional and biological role of a candidate lncRNA. We established and validated this strategy using lncRNA *Urothelial Cancer Associated 1* (*UCA1*) as a proof of concept. We found *UCA1* overexpression is a driver of ovarian cancer development. The reverse phase protein array (RPPA) profiling revealed deregulation of Hippo-YAP signaling when *UCA1* is depleted. Characterization of *UCA1* interacting proteins identified a mechanism of regulation of Hippo-YAP signaling *via* physical interactions between *UCA1* and angiomotin (AMOT), a non-canonical RNA-binding protein. The LncRNA Interpreter approach can therefore efficiently provide critical mechanistic insights for characterization of candidate lncRNAs.

Results {#sec2}
=======

LncRNA Interpreter, a Strategy for Mechanistic Analysis of LncRNAs {#sec2.1}
------------------------------------------------------------------

An overview of LncRNA Interpreter strategy is shown in [Figure 1](#fig1){ref-type="fig"}. Following lncRNA identification (e.g., from analysis of patient data or analyses of super-enhancer-associated lncRNAs), lncRNA knockout (KO) models are generated for disease-relevant phenotypic characterization. The RPPA is utilized to evaluate differentially expressed proteins and downstream pathways affected by disruption of lncRNAs. Most key cancer pathways are surveyed on the RPPA ([@bib45]), which enables quantification of several protein post-translational modifications that are crucial for signaling cascades commonly deregulated in cancer ([@bib5]). We developed *in vivo* RNA antisense purification (iRAP) from previously developed RNA-centric methods ([@bib7], [@bib37], [@bib38]) to catalog the interacting proteome of candidate lncRNAs. As protein-RNA interactions are essential for lncRNA functionality, intersection of proteins/pathways identified using RPPA with iRAP profiles provides an efficient approach for dissecting the underlying mechanism of candidate lncRNAs implicated in complex diseases such as cancer.Figure 1LncRNA Interpreter, a Strategy for Mechanistic Analysis of lncRNAsThe LncRNA Interpreter strategy consists of five major components. (A) Discovery of candidate lncRNAs is performed using patient specimens. (B) Phenotypic characterization of the candidate lncRNA is performed *in vitro* and *in vivo* using KO cancer cell models generated using CRISPR/Cas9 genome editing technique. (C) Proteins affected by candidate lncRNA are identified by functional proteomics using RPPA. (D) LncRNA interacting proteins are identified using iRAP. (E) RPPA and iRAP data are integrated to identify common protein targets. ChIP-seq, chromatin immunoprecipitation sequencing; RNA-Seq, RNA sequencing; RPPA, reverse phase protein array; iRAP, *in vivo* RNA antisense purification; WT, wild-type; KO, knockout; RBP, RNA-binding protein; RIP, RNA immunoprecipitation; MS, mass spectrometry; WB, western blotting; RT-qPCR, reverse transcription quantitative polymerase chain reaction.

*UCA1* Is a Driver of Ovarian Cancer Development and Outcome {#sec2.2}
------------------------------------------------------------

We evaluated data from The Cancer Genome Atlas ([@bib3]) to identify candidate lncRNAs that drive the development and clinical outcome (survival) in high-grade serous EOC cases. We identified an lncRNA signature comprising 50 lncRNAs associated with patient prognosis ([Figure 2](#fig2){ref-type="fig"}A, [Table S1](#mmc1){ref-type="supplementary-material"}). Since super-enhancers mark pivotal oncogenes in many tumor types ([@bib23], [@bib33], [@bib46], [@bib63]), we integrated lncRNA expression data with genome-wide profiles of enhancer marks generated using chromatin immunoprecipitation sequencing (ChIP-seq) for H3K27ac in primary high-grade serous EOC tissues to identify super-enhancers that drive candidate oncogenic lncRNA expression. Ninety-three super-enhancers identified in high-grade serous EOC tissues were associated with lncRNA expression ([Figure 2](#fig2){ref-type="fig"}A, [Table S2](#mmc1){ref-type="supplementary-material"}), of which three, *UCA1, SNHG9,* and *SNHG15*, were also associated with prognosis ([Figure 2](#fig2){ref-type="fig"}A, [Table S1](#mmc1){ref-type="supplementary-material"}). *UCA1* is of particular interest as this lncRNA has been implicated in the development of other cancers ([@bib6], [@bib12], [@bib19], [@bib22], [@bib29], [@bib30], [@bib31], [@bib41], [@bib42], [@bib54], [@bib55], [@bib57], [@bib68], [@bib72], [@bib73]), although its functional targets remain elusive. The *UCA1* locus is marked by a super-enhancer in all major histotypes of ovarian cancer---clear cell, endometrioid, high-grade serous, and mucinous---but not in precursor tissues---fallopian tube secretory epithelial cells (FTSECs) or ovarian surface epithelial cells (OSECs) ([Figure 2](#fig2){ref-type="fig"}B). *UCA1* expression positively correlates with super-enhancer signal at this locus (r = 0.51, p = 0.026, Spearman\'s correlation) ([Figure 2](#fig2){ref-type="fig"}C), suggesting that this tumor-specific super-enhancer regulates *UCA1* expression. Super-enhancer-associated genes are particularly responsive to treatment of (+)-JQ1 ([@bib33]), a potent inhibitor of BET family of bromodomain proteins including BRD4 ([@bib14]); we found that *UCA1* expression was significantly downregulated in two ovarian cancer cell lines treated with (+)-JQ1 compared with dimethyl sulfoxide (DMSO)-treated control cells ([Figure 2](#fig2){ref-type="fig"}D). The expression of a neighboring gene *OR10H1* (∼20 kb upstream), which has no super-enhancer at its locus ([Figure S1](#mmc1){ref-type="supplementary-material"}A) and shows some evidence of correlation with the *UCA1* super-enhancer (r = 0.47, p = 0.043, Spearman\'s correlation) ([Figure S1](#mmc1){ref-type="supplementary-material"}B), was not affected by (+)-JQ1 treatment ([Figure 2](#fig2){ref-type="fig"}D). Together these analyses suggesting the super-enhancer at this locus drives the expression of *UCA1* in ovarian cancer.Figure 2*UCA1* in Ovarian Cancer Development and Outcome(A) In high-grade serous EOCs a signature of 50 lncRNAs was prognostic. Using tumor tissue H3K27ac data, 93 high-grade serous EOC super-enhancer-associated lncRNAs were identified. 3 lncRNAs were shared between the two analyses.(B) *UCA1*-associated super-enhancer is present across the four major histological subtypes of EOC, but not normal precursor cells. H3K27ac ChIP-seq signal is shown in log scale. CCOC, clear cell ovarian cancer; EnOC, endometrioid ovarian cancer; HGSOC, high-grade serous ovarian cancer; MOC, mucinous ovarian cancer.(C) Super-enhancer signal positively correlates with *UCA1* expression (Spearman\'s correlation, r = 0.51, p = 0.026). Counts per million (CPM) of *UCA1* from RNA-seq is shown. Super-enhancer signals were normalized using TMM ([@bib48]). We did not have sufficient tissue to do RNA-seq for one EnOC tumor (\#3), and one HGSOC tumor (\#4) does not express *UCA1*.(D) *UCA1* expression is sensitive to JQ1 treatment in HGSOC models. Two HGSOC cell lines (CaOV3, UWB1.289) were treated with (+)-JQ1 or DMSO. The expression of *UCA1* and *OR10H1* was measured by RT-qPCR.Data shown here are mean ± SD from three independent experiments. \*\*\*p = 1×10^−7^ (CaOV3), \*\*\*p = 2×10^−8^ (UWB1.289), ns, not significant, Student\'s t test. See also [Figure S1](#mmc1){ref-type="supplementary-material"}, [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Deletion of *UCA1* Impairs Ovarian Cancer Cell Growth {#sec2.3}
-----------------------------------------------------

CRISPR/Cas9 genome editing was used to create stable *UCA1* KO models in ovarian cancer cell lines OVCA429 and OVISE ([Figures 3](#fig3){ref-type="fig"}A and 3B). *UCA1* expression was undetectable in all *UCA1* KO models ([Figure 3](#fig3){ref-type="fig"}C). The effects of *UCA1* KO on *in vivo* tumor cell growth were established after intra-peritoneal injection of 10 million wild-type (WT) *UCA1* or *UCA1* KO cells in nude mice. The mass of resulting tumors was significantly smaller in *UCA1* KO models compared with those in mice injected with WT cells (OVCA429 p = 0.002; OVISE p = 0.002) ([Figures 3](#fig3){ref-type="fig"}D and 3E), indicating that *UCA1* acts as a potent promoter of tumor seeding and/or growth *in vivo*.Figure 3Inactivation of *UCA1* Impairs Ovarian Cancer Cell Growth(A) Schematic of CRISPR/Cas9 genome editing strategy for *UCA1* knockout.(B) Long-range PCR of parental (OVCA429 and OVISE) cells, control cells expressing the gRNA vector backbone, and two stable *UCA1* knockout clones from each cell line (*UCA1* KO-1, *UCA1* KO-2).(C) The expression of *UCA1,* measured by RT-qPCR, was normalized to the expression of GAPDH and β-actin in the *UCA1* KO models, parental cells, and control cells. Data shown are mean ± SD from three independent experiments.(D) Images of excised tumors from mouse xenograft model. Scale bar represents 1 cm.(E) Tumor weight of xenografted *UCA1* KO ovarian cancer cells and parental controls. \*\*p \< 0.01, Student\'s t test.

*UCA1* Regulates Hippo-YAP Signaling in Ovarian Cancer {#sec2.4}
------------------------------------------------------

We used RPPAs to profile changes in protein abundance and phosphorylation following *UCA1* KO. The most differentially expressed proteins between WT and *UCA1* KO cells included phosphorylated YAP at Ser127 (YAPpS127, fold change \[FC\] = 1.3, p = 0.038), AXL (FC = 0.75, p = 0.031), and PUMA (FC = 1.18, p = 0.042), all of which belong to the Hippo-YAP signaling pathway ([Figure 4](#fig4){ref-type="fig"}A, [Table S3](#mmc1){ref-type="supplementary-material"}). YAPpS127 is retained in the cytoplasm via binding to 14-3-3 protein, which leads to inhibition of downstream YAP signaling ([@bib71]). We observed an increased expression of YAPpS127 and pro-apoptotic YAP target gene PUMA ([@bib36]) and decreased expression of the pro-proliferative YAP target gene AXL ([@bib64]) in *UCA1* KO compared with WT cells ([Figure 4](#fig4){ref-type="fig"}A), indicating that *UCA1* activates Hippo-YAP signaling for cell survival and proliferation. Consistent with this, YAPpS127 protein expression is significantly lower in primary tumors with *UCA1* overexpression or amplification (n = 105, average abundance −0.25) compared with tumors with no *UCA1* overexpression (n = 477, average abundance 0.07, p = 2.8×10^−4^, *Q* = 0.019) ([Figure S2](#mmc1){ref-type="supplementary-material"}A). There was no significant difference in total YAP protein expression between the two groups ([Figure S2](#mmc1){ref-type="supplementary-material"}B), suggesting that *UCA1* also activates YAP signaling *in vivo*.Figure 4*UCA1* Activates Hippo-YAP Signaling in Ovarian Cancer(A) RPPA analyses of OVCA429 *UCA1* KO cells and controls. All proteins with significant changes (FC \> 1.2 or \<0.9 and p ≤ 0.05) in abundance are shown. Proteins highlighted in blue are involved in Hippo-YAP signaling.(B) The expression of *UCA1* was measured by RT-qPCR and normalized to β-actin in both scramble control siRNA (siCtrl) and *UCA1*-specific siRNA (si*UCA1*)-transfected CaOV3, OVCA429, and UBW1.289 cells. Data shown are mean ± SD from three independent experiments.(C) The expression of YAP, YAPpSer127, and YAP targets by western blotting in both siCtrl and si*UCA1*-transfected cells. Representative results from three independent experiments are shown. When *UCA1* was knocked down, YAPpSer127 expression was elevated 90% (p \< 0.01), 150% (p \< 0.001), and 50% (p \< 0.05) in CaOV3, OVCA429, and UWB1.289 cells, respectively. Student\'s t test.(D) The expression of YAP targets AXL and CYR61 was measured by RT-qPCR in siCtrl and siYAP-transfected cells and normalized to β-actin. Data shown are mean ± SD from three independent experiments. \*\*p \< 0.01, \*\*\*p \< 0.001, Student\'s t test.(E) The expression of YAP and YAP targets by western blotting in CaOV3, OVCA429, and UBW1.289 cells transfected with siCtrl or siYAP.(F) The C~t~ values of *UCA1* lncRNA in both OSEC4C2 control cells and OSEC4C2 cells with *UCA1* overexpression. ND, not detected. Data shown are mean ± SD from three independent experiments and normalized to *18S* rRNA.(G) The expression of YAP, YAPpSer127, and YAP targets by western blotting in both OSEC4C2 control cells and OSEC4C2 cells with *UCA1* overexpression. β-Actin was used as loading control for western blotting.See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S3](#mmc1){ref-type="supplementary-material"}.

Since the presence of a non-unique intronic sequence mandated the introduction of a \>5 kb deletion to KO *UCA1*, it is plausible that noncoding elements within the *UCA1* locus activate YAP target genes in *cis* or in *trans*. To test this possibility, loss-of-function experiments using small interfering RNAs (siRNAs) specific to *UCA1* were conducted to validate the role of *UCA1* in regulation of Hippo-YAP signaling. After *UCA1* knockdown (KD) in high-grade serous ovarian cancer cell lines ([Figure 4](#fig4){ref-type="fig"}B), total YAP expression was unaltered, whereas YAPpS127 was elevated at least 50% in all three ovarian cancer cell lines (by ImageJ) ([Figure 4](#fig4){ref-type="fig"}C), consistent with RPPA results in *UCA1* KO cells and primary tissues. YAP regulates the expression of AXL and CYR61 at both RNA ([Figure 4](#fig4){ref-type="fig"}D) and protein levels ([Figure 4](#fig4){ref-type="fig"}E), indicating that AXL and CYR61 are indeed YAP targets in ovarian cancer. The effect of *UCA1* KD on the abundance of AXL and CYR61 largely phenocopied YAP KD ([Figures 4](#fig4){ref-type="fig"}C and 4E). Moreover, gain-of-function experiments performed by overexpressing *UCA1* in TERT-immortalized, MYC-expressing normal ovarian epithelial cells (OSEC4C2) ([Figure 4](#fig4){ref-type="fig"}F) demonstrated that overexpression of *UCA1* increased the expression of YAP target genes AXL, CYR61, as well as CTGF ([Figure 4](#fig4){ref-type="fig"}G). Consistent with the loss-of-function experiments, overexpression of *UCA1* inhibits YAP phosphorylation but does not affect total YAP expression ([Figure 4](#fig4){ref-type="fig"}G). Taken together, these data indicate that *UCA1* activates Hippo-YAP signaling in ovarian cancer.

iRAP Catalogs the *UCA1* Interacting Proteome {#sec2.5}
---------------------------------------------

Proteins purified from two independent *UCA1-*iRAP experiments were profiled by mass spectrometry. Each iRAP experiment included two non-overlapping *UCA1* probe sets (*UCA1*-odd, *UCA1*-even) for cross-validation and a *U1* probe as positive control ([Figure S3](#mmc1){ref-type="supplementary-material"}A, [Table S4](#mmc1){ref-type="supplementary-material"}). The iRAP assay was highly specific: both *UCA1* probe sets significantly enriched *UCA1* but not *U1* snRNA; conversely, the *U1* probe enriched *U1* snRNA but not *UCA1*. As expected, *U6* snRNA was not enriched by any of the probes ([Figure S3](#mmc1){ref-type="supplementary-material"}B). iRAP-MS recovered 86 *U1-*associated proteins ([Figure 5](#fig5){ref-type="fig"}A), including six known *U1* direct binding proteins and another 35 *U1*-associated proteins ([Figure S3](#mmc1){ref-type="supplementary-material"}C, [Table S5](#mmc1){ref-type="supplementary-material"}) ([@bib7]). These data indicate that iRAP efficiently identifies *bona fide* RNA-binding proteins associated with a specific target transcript. We isolated 47 and 42 proteins, respectively, using *UCA1*-odd and *UCA1*-even probe sets ([Figure 5](#fig5){ref-type="fig"}A). Thirty-eight proteins were only associated with *UCA1*, 19 of which were identified by both sets of probes ([Figure 5](#fig5){ref-type="fig"}A). In most instances the same peptide was retrieved by both *UCA1* probe sets across the two experiments ([Figures 5](#fig5){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}D, [Table S5](#mmc1){ref-type="supplementary-material"}), suggesting that these 19 proteins are true *UCA1*-binding proteins.Figure 5*UCA1* Interacts Directly with Hippo-YAP Signaling Regulator AMOTp130(A) iRAP followed by mass spectrometry to catalog the *UCA1* interactome.(B) The same AMOT peptides were reproducibly retrieved from *UCA1* iRAP. Numbers indicate the amino acid position; protein not drawn to scale. Data shown are from two independent experiments.(C) Western blotting validation of AMOT as a direct binding protein for *UCA1* using iRAP samples. U1-70k, a known direct binding protein for *U1* snRNA, is used as positive control for *U1*. As expected, GAPDH binds neither *U1* nor *UCA1*.(D and E) RIP validation of the AMOT-lncRNA *UCA1* interaction. (D) Western blotting validation of AMOT pull-down, using an AMOT specific antibody, in three high-grade serous EOC cell lines. Isotype IgG was included as negative control. Numbers beneath the blots are the relative ratios for AMOTp130:AMOTp80. (E) Relative expression of *UCA1* in AMOT immunoprecipitated RNA samples by RT-qPCR.(F and G) RIP validation of AMOTp130-*UCA1* interaction. (F) Western blotting validation of GFP-tagged AMOT pull-down with an anti-GFP antibody. Representative images from three independent experiments are shown. Control cells were transduced with a GFP expressing vector only. (G) Relative expression of *UCA1* for GFP-RIP samples by RT-qPCR. \# denotes a non-specific band observed with this GFP antibody. (H-I) RIP validation of YAP-AMOTp130-*UCA1* complex.(H) Western blotting validation of YAP pull-down and AMOT co-immunoprecipitated using a YAP specific antibody. Isotype IgG was included as negative control.(I) RT-qPCR measurement of relative expression of *UCA1* in YAP-RIP samples.(J) RIP following RNase A treatment, *UCA1* is not required for the YAP-AMOTp130 interaction. Western blotting validation of YAP pull-down and AMOT co-immunoprecipitated by YAP specific antibody, with or without RNase A treatment. Isotype IgG was included as negative control.(K) Relative expression of *UCA1* by RT-qPCR in YAP RIP samples, incubated with or without RNase A.Data shown are mean ± SD from three independent experiments. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, Student\'s t test. See also [Figure S3](#mmc1){ref-type="supplementary-material"}, [Tables S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.

*UCA1* Interacts Directly with Hippo-YAP Signaling Regulator AMOTp130 {#sec2.6}
---------------------------------------------------------------------

We intersected the *UCA1* interacting proteome with the pathways identified in the RPPA profiling described earlier. This highlighted AMOT, a known regulator of Hippo-YAP signaling ([@bib40], [@bib70]). A peptide mapping to amino acids 727--740 of AMOT was identified by both *UCA1* probe sets in two independent experiments ([Figure 5](#fig5){ref-type="fig"}B), suggesting this predicted coiled-coil domain of AMOT is responsible for the interaction with *UCA1*. AMOT exists as two isoforms, AMOTp130 and AMOTp80, a shorter isoform that lacks 409 amino acids at the N terminus due to alternative splicing of the *AMOT* gene between exon 2 and 3 ([@bib10]). Western blotting of iRAP lysates validated the AMOT-*UCA1* interaction. We observed shifted AMOTp130 (to around 160 kDa) but not AMOTp80, suggesting that *UCA1* associates specifically with AMOTp130 ([Figure 5](#fig5){ref-type="fig"}C). To further verify the AMOT-*UCA1* interaction, we performed RNA immunoprecipitation (RIP) using an anti-AMOT antibody ([Table S6](#mmc1){ref-type="supplementary-material"}). Western blotting for AMOT confirmed successful pull-down of both AMOTp80 and AMOTp130 isoforms ([Figure 5](#fig5){ref-type="fig"}D), and an ∼2- to 5-fold enrichment of *UCA1* was detected in AMOT-RIP samples compared with corresponding control isotype IgG pulldowns (CaOV3, p = 7.4×10^−6^; OVCA429, p = 0.011; UWB1.289, p = 7.2×10^−7^) ([Figure 5](#fig5){ref-type="fig"}E). We noted that a higher ratio of AMOTp130/p80 correlates with a higher fold enrichment of *UCA1* ([Figures 5](#fig5){ref-type="fig"}D and 5E), further suggesting that *UCA1* preferentially associates with AMOTp130. To validate this, we overexpressed GFP-AMOTp130 or GFP-AMOTp80 in EOC cells and performed GFP-RIP. Western blotting validated successful pull-down of both GFP-AMOTp80 and GFP-AMOTp130 ([Figure 5](#fig5){ref-type="fig"}F) with significant enrichment of *UCA1* observed for GFP-AMOTp130 but not GFP-AMOTp80 ([Figure 5](#fig5){ref-type="fig"}G), despite the markedly more efficient pull-down of AMOTp80 ([Figure 5](#fig5){ref-type="fig"}F). These data together indicate that *UCA1* interacts directly with AMOTp130 but not AMOTp80.

AMOTp130 but not AMOTp80 was previously reported to interact with YAP and regulate its activity ([@bib50], [@bib70]). We tested whether this interaction is intact in EOC. In YAP-RIP experiments, AMOTp130 was detected in YAP pull-downs ([Figure 5](#fig5){ref-type="fig"}H), confirming that YAP interacts with AMOTp130. AMOTp80 was also detected in YAP pull-downs for two of the three cell lines, which may be due to hetero-oligomerization ([@bib11], [@bib44], [@bib74]). Interestingly, a 4- to 29-fold enrichment of *UCA1* was detected in YAP pulldowns compared with IgG isotype controls ([Figure 5](#fig5){ref-type="fig"}I). Since we did not identify YAP using iRAP (which preferentially detects direct binding proteins), these data suggest that YAP, AMOTp130, and *UCA1* form a trimer complex with AMOTp130 bridging the interaction between YAP and *UCA1*. Once formed, the AMOTp130-YAP interaction is independent of *UCA1* since the association still exists following RNase A treatment ([Figures 5](#fig5){ref-type="fig"}J and 5K).

*UCA1* Activates YAP and Target Genes by Enhancing the AMOTp130-YAP Interaction to Promote YAP Dephosphorylation and Nuclear Translocation {#sec2.7}
------------------------------------------------------------------------------------------------------------------------------------------

We next tested whether AMOT is required for activation of YAP target genes by *UCA1*. Western blotting and RT-qPCR validated the successful depletion of AMOT ([Figure 6](#fig6){ref-type="fig"}A) and *UCA1* ([Figure 6](#fig6){ref-type="fig"}B), respectively. Both *UCA1* and AMOT KD resulted in reduced expression of AXL and CYR61 and elevated the expression of YAPpS127 40%--100% but had no effect on total expression levels of YAP, YAP kinase LATS1, or active pLATS1 ([Figure 6](#fig6){ref-type="fig"}A). Although the expression of *UCA1* was not affected by AMOT KD ([Figure 6](#fig6){ref-type="fig"}B), the activation of YAP target genes was dampened ([Figure 6](#fig6){ref-type="fig"}A), indicating that AMOT mediates the activation of YAP target genes by *UCA1*.Figure 6*UCA1* Activates YAP and Its Target Genes by Facilitating AMOTp130-YAP Interaction to Promote YAP Dephosphorylation and Nuclear Translocation(A) AMOT mediates the activation of YAP and its target genes by *UCA1*. OC cells were transfected with siCtrl, siAMOT, or si*UCA1* for 72 h. Whole-cell lysates were prepared and blotted with antibodies indicated. When *UCA1* or AMOT is knocked down, YAPpSer127 expression is elevated 80% (p \< 0.01), 100% (p \< 0.01), and 40% (p \< 0.01) in CaOV3, OVCA429, and UWB1.289 cells, respectively.(B) Validation of siRNA knockdown efficiency for *UCA1*. Relative expression of *UCA1* by RT-qPCR for samples is shown in (A).(C) *UCA1* KO in OVCA429 cells decreases nuclear YAP. *UCA1* wild-type (Ctrl1, Ctrl2) or knockout (KO-1, KO-2) OVCA429 cells were fractionated into cytoplasmic (Cy) and nuclear (Nu) fractions and blotted for β-tubulin (a cytoplasmic marker), U1-70k (a nuclear marker), and YAP.(D) Quantification of nuclear YAP using ImageJ.(E) *UCA1* KD decreases nuclear YAP. CaOV3, OVCA429, and UWB1.289 cells transfected with control siRNAs or si*UCA1* were fractionated into cytoplasmic and nuclear fractions and blotted for β-tubulin, U1-70k, AMOT, and YAP. Nuclear YAP is reduced 50% (CaOV3, p \< 0.05) and 70% (UWB1.289, p \< 0.05) in cells transfected with si*UCA1*.(F) *UCA1* overexpression in OSEC4C2 cells increases nuclear YAP. OSEC4C2 control cells and OSEC4C2 cells with *UCA1* overexpression were fractionated into Cy and Nu fractions and blotted for β-tubulin, U1-70k, and YAP. Nuclear YAP is elevated 30% (p \< 0.05).(G) *UCA1* facilitates AMOTp130 binding to YAP. High-grade serous EOC cell lines were transfected with siCtrl or si*UCA1* for 72 h. Co-immunoprecipitation experiments were performed using an anti-YAP antibody. Retrieval of AMOT is reduced 70% (CaOV3, p \< 0.05) and 50% (UWB1.289, p \< 0.05) in cells transfected with si*UCA1*.(H) Working model for AMOT-mediated activation of YAP and target genes by *UCA1*.SE, super-enhancer. ImageJ was used for quantification of proteins in (A, C, E, F, and G) from three independent replicates. Data shown in (B and D) are mean ± SD from three independent experiments. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, ns, not significant, Student\'s t test. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

When phosphorylated at Ser127, YAP protein is retained in the cytoplasm and downstream signaling is repressed ([@bib71]). When total YAP protein levels are constant, increased YAPpS127 should result in reduced nuclear YAP. We therefore compared nuclear YAP expression between control and *UCA1* KO cells using cellular fractionation. Successful fractionation of the OVCA429 KO model was verified using cytoplasmic protein marker β-tubulin and nuclear protein marker U1-70k ([Figure 6](#fig6){ref-type="fig"}C) as well as cytoplasmic RNA marker *18S* rRNA and nuclear RNA marker *U6* snRNA ([Figure S4](#mmc1){ref-type="supplementary-material"}A). These data show that *UCA1* predominantly localizes to the cytoplasm (∼94% on average, [Figure S4](#mmc1){ref-type="supplementary-material"}A). Nuclear YAP expression decreased ∼2-fold in *UCA1* KO cells (KO-1 and KO-2) compared with WT cells (Ctrl 1 and Ctrl 2) (p = 3×10^−4^) ([Figures 6](#fig6){ref-type="fig"}C and 6D). In addition, fractionation experiments were performed in three ovarian cancer cell lines following *UCA1* KD. Similarly, nuclear YAP was reduced 2-fold in *UCA1* KD CaOV3 and 3-fold in *UCA1* KD UWB1.289 cells compared with control siCtrl-treated cells (p = 0.014 and p = 0.006, respectively) ([Figure 6](#fig6){ref-type="fig"}E). Fractionation experiments were also conducted in OSEC4C2 cells overexpressing with control vector or *UCA1* ([Figures 6](#fig6){ref-type="fig"}F and [S4](#mmc1){ref-type="supplementary-material"}B). Predominant cytoplasmic expression *UCA1* was confirmed in OSEC4C2 cells overexpressing *UCA1* ([Figure S4](#mmc1){ref-type="supplementary-material"}B) and nuclear YAP was increased ([Figure 6](#fig6){ref-type="fig"}F). These data indicate that cytoplasmic *UCA1* activates YAP target genes *via* dephosphorylation and nuclear translocation of YAP.

Since *UCA1* KD affects neither AMOT protein expression ([Figure 6](#fig6){ref-type="fig"}A) nor localization ([Figure 6](#fig6){ref-type="fig"}E), we tested whether *UCA1* affects the AMOT-YAP interaction. Two-fold less AMOTp130 coimmunoprecipitated with YAP when *UCA1* was depleted ([Figure 6](#fig6){ref-type="fig"}G), evidence that *UCA1* promotes AMOTp130-YAP interaction. In summary, we propose a model in which cytoplasmic *UCA1* binds to AMOT to facilitate an interaction between AMOT and YAP, which prevents the pLATS1/2-YAP interaction and YAP phosphorylation. The net result is a larger pool of active YAP, which relocates to the activate YAP target genes ([Figure 6](#fig6){ref-type="fig"}H).

Discussion {#sec3}
==========

*UCA1* is conserved in primates and expressed highly in the early embryo but not in most adult tissues ([@bib56]). Originally *UCA1* was found to be overexpressed in bladder carcinoma ([@bib60]) and was later shown to be upregulated in many other malignancies ([@bib6], [@bib12], [@bib19], [@bib22], [@bib29], [@bib30], [@bib31], [@bib41], [@bib42], [@bib54], [@bib55], [@bib57], [@bib68], [@bib72], [@bib73]). Multiple underlying mechanisms have been proposed to explain the pro-oncogenic effects of *UCA1*, including inhibition of p27 ([@bib19]), activation of Wnt/β-Catenin signaling ([@bib66]), promotion of KLF4-KRT6/13 signaling ([@bib41]), or function as miRNA sponge ([@bib1], [@bib13], [@bib21], [@bib27], [@bib28], [@bib26], [@bib34], [@bib42], [@bib51], [@bib53], [@bib55], [@bib57], [@bib61], [@bib62], [@bib65], [@bib69], [@bib75], [@bib76], [@bib77]). However, the mechanistic pathways directly regulated by *UCA1* are unclear.

In our study, we found that *UCA1* overexpression drives ovarian cancer development. Our functional proteomic analyses of *UCA1* KO models revealed that *UCA1* activates YAP and its target genes, which may account for *UCA1*\'s tumor growth promotion phenotype. To dissect the underlying mechanism of how *UCA1* activates YAP and its target gens, iRAP was performed and revealed that *UCA1* directly interacts with AMOTp130. AMOT was initially reported as a negative regulator of YAP *via* cytoplasmic retention of YAP protein ([@bib70]). However, more recent evidence suggests that AMOT can both negatively ([@bib4], [@bib8], [@bib43], [@bib59]) and positively regulate ([@bib35], [@bib67]) YAP. In the present study, we demonstrated that AMOT is a positive regulator of YAP and its targets genes in ovarian cancer. In the cytoplasm of EOC cells, overexpressed *UCA1* enhances the interaction between AMOTp130 and YAP. This may be due to a conformational change of AMOTp130 induced by *UCA1* binding; alternatively, *UCA1* may affect the phosphorylation of AMOTp130, which in turn regulates AMOTp130-YAP interaction and subcellular localization of the complex ([@bib8], [@bib40]). However, the latter situation is unlikely as *UCA1* does not affect AMOT localization in EOC ([Figure 6](#fig6){ref-type="fig"}E). The enhanced AMOTp130-YAP interaction is therefore more likely to antagonize the pLATS1/2-YAP interaction that leads to phosphorylation of YAP ([@bib67]) since overlapping regions of YAP bind to AMOT or LATS1/2 ([@bib20], [@bib70]). The indirect impact of *UCA1* is therefore dephosphorylation of YAP, which in turn promotes nuclear translocation of YAP and facilitates its binding to TEAD to activate expression of a pro-oncogenic gene signature.

In the current study, we develop a strategy LncRNA Interpreter to prioritize and then functionally dissect candidate lncRNAs in cancer. Using this approach, we reveal *UCA1* as a super-enhancer-regulated lncRNA in EOC and an unconventional lncRNA regulator of Hippo-YAP signaling and characterize a critical function for *UCA1* in the activation of YAP and its target genes in EOC. Our data implicate the *UCA1*-AMOTp130-YAP signaling axis in the development of EOC that may represent a potential target for therapeutic intervention. More broadly, this proof-of-concept study demonstrates that the protein-centric LncRNA Interpreter strategy can be readily applied to efficiently elucidate the functional role of other lncRNAs implicated in complex diseases.

Limitations of the Study {#sec3.1}
------------------------

In this study, we demonstrated that *UCA1* activates the transcription coactivator YAP and its target genes in both gain-of-function and loss-of-function experiments. It is plausible that *UCA1* prevents YAP phosphorylation by pLATS1/2, but direct evidence for this is missing owing to the low expression of LATS1/2 in our models. Future studies evaluating YAP and AMOTp130 post-transcriptional modifications would likely yield a deeper mechanistic insight into the regulation of Hippo-YAP signaling pathway by *UCA1*.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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